Han Dai is Senior Director, New Ventures, Johnson & Johnson Innovation Asia Pacific, responsible for developing and implementing Innovation strategies and the identifying and evaluating of external opportunities in China.  

Han has 20 years’ experience in Pharma/Biotech industry with track records of successful leadership in small molecule & biologics drug discovery & development and high-profile publications. Prior to joining Johnson & Johnson Innovation, Han was Executive Director at BeiGene. Prior to that, he held multiple roles with increasing responsibilities as Scientific Leader and GSK Fellow of Protein Degradation DPU/Future Pipeline Discovery team at GlaxoSmithKline US headquarter.

Han received his Ph.D. in Molecular Biophysics from UT Southwestern Medical Center as Frank and Sara McKnight fellow, and his B.S. in Biochemistry from Department for Intensive Instruction, Nanjing University. Han completed his postdoctoral training in Harvard Medical School and HHMI as Helen Hay Whitney fellow. He has published more than 40 papers, book chapter, abstracts and patents in reputable journals and conferences. Han served as Scientific Advisory Board member of the Chemical Probes Portal, Full Faculty Member of F1000 Drug Discovery & Design Section, President of Sino-American Pharmaceutical Professional Association – Greater Philadelphia (SAPA-GP) and VP of SAPA-HQ. He is also a visiting professor at High Magnetic Field Laboratory of the Chinese Academy of Sciences (CHMFL).